Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shusuke Numata

Showing results (111-120 of 144) with videos related to

Pageof 15
Sort By:
JMIR Mental Health|May 30, 2024
Tablet-Based Cognitive and Eye Movement Measures as Accessible Tools for Schizophrenia Assessment: Multisite Usability StudyKentaro Morita, Kenichiro Miura, Atsuhito Toyomaki, et al.
Nature Communications|February 4, 2016
Emerging roles of ARHGAP33 in intracellular trafficking of TrkB and pathophysiology of neuropsychiatric disordersTakanobu Nakazawa, Ryota Hashimoto, Kazuto Sakoori, et al.
Heliyon|January 30, 2023
Interferon signaling and hypercytokinemia-related gene expression in the blood of antidepressant non-respondersHirotaka Yamagata, Ryouichi Tsunedomi, Toshiharu Kamishikiryo, et al.
Nature Communications|April 21, 2016
Corrigendum: Emerging roles of ARHGAP33 in intracellular trafficking of TrkB and pathophysiology of neuropsychiatric disordersTakanobu Nakazawa, Ryota Hashimoto, Kazuto Sakoori, et al.
BMC Psychiatry|October 9, 2025
Maintenance pharmacotherapy after electroconvulsive therapy in inpatients with major depressive disorder: 198 prescriptions in a real-world clinical settingShun Igarashi, Takashi Tsuboi, Naomi Hasegawa, et al.
JAMA Network Open|August 5, 2025
Guided Internet-Based Cognitive Behavior Therapy for Women With Bulimia Nervosa: A Randomized Clinical TrialSayo Hamatani, Kazuki Matsumoto, Gerhard Andersson, et al.
The International Journal of Neuropsychopharmacology|March 28, 2025
Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide studyShinichiro Ochi, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|December 2, 2021
Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation studyNorio Yasui-Furukori, Hiroyuki Muraoka, Naomi Hasegawa, et al.
Asian Journal of Psychiatry|July 29, 2021
Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|March 11, 2021
Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation studyShusuke Numata, Masahito Nakataki, Naomi Hasegawa, et al.
Pageof 15

Showing results (111-120 of 144) with videos related to

Sort By:
Pageof 15
JMIR Mental Health|May 30, 2024
Tablet-Based Cognitive and Eye Movement Measures as Accessible Tools for Schizophrenia Assessment: Multisite Usability StudyKentaro Morita, Kenichiro Miura, Atsuhito Toyomaki, et al.
Nature Communications|February 4, 2016
Emerging roles of ARHGAP33 in intracellular trafficking of TrkB and pathophysiology of neuropsychiatric disordersTakanobu Nakazawa, Ryota Hashimoto, Kazuto Sakoori, et al.
Heliyon|January 30, 2023
Interferon signaling and hypercytokinemia-related gene expression in the blood of antidepressant non-respondersHirotaka Yamagata, Ryouichi Tsunedomi, Toshiharu Kamishikiryo, et al.
Nature Communications|April 21, 2016
Corrigendum: Emerging roles of ARHGAP33 in intracellular trafficking of TrkB and pathophysiology of neuropsychiatric disordersTakanobu Nakazawa, Ryota Hashimoto, Kazuto Sakoori, et al.
BMC Psychiatry|October 9, 2025
Maintenance pharmacotherapy after electroconvulsive therapy in inpatients with major depressive disorder: 198 prescriptions in a real-world clinical settingShun Igarashi, Takashi Tsuboi, Naomi Hasegawa, et al.
JAMA Network Open|August 5, 2025
Guided Internet-Based Cognitive Behavior Therapy for Women With Bulimia Nervosa: A Randomized Clinical TrialSayo Hamatani, Kazuki Matsumoto, Gerhard Andersson, et al.
The International Journal of Neuropsychopharmacology|March 28, 2025
Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide studyShinichiro Ochi, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|December 2, 2021
Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation studyNorio Yasui-Furukori, Hiroyuki Muraoka, Naomi Hasegawa, et al.
Asian Journal of Psychiatry|July 29, 2021
Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|March 11, 2021
Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation studyShusuke Numata, Masahito Nakataki, Naomi Hasegawa, et al.
Pageof 15